Innate Pharma Releases Its 2026 Financial Calendar

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication of revenue and cash position for 1Q2026 May 21, 2026: Annual General Shareholders Meeting September 17, 2026: Publication of half year financial statements November 5, 2026: Publication of revenue and cash position for 3Q2026 All financia.

Business Wire • Dec 11, 2025

Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025

MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of November 27, 2025.

Business Wire • Nov 28, 2025

Innate Pharma to Present at Jefferies Global Healthcare Conference

MARSEILLE, France--(BUSINESS WIRE)-- #Congress--Innate Pharma to present at Jefferies Global Healthcare Conference.

Business Wire • Nov 17, 2025

Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript

Innate Pharma S.A. ( IPHA ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Stephanie Cornen - Vice President of Investor Relations, Communication & Commercial Strategy Jonathan Dickinson - CEO & Director Sonia Quaratino - Executive VP & Chief Medical Officer Conference Call Participants Christopher Liu - Lucid Capital Markets, LLC, Research Division Justin Zelin - BTIG, LLC, Research Division Swayampakula Ramakanth - H.C.

Seeking Alpha • Nov 13, 2025

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results for the first nine months of 2025. “This quarter highlights strong execution across our key programs,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “With FDA clearance to initiate TELLOMAK-3, we are advancing lacutamab toward its confirmatory Phase 3 and potential accelerated approval.

Business Wire • Nov 13, 2025

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL), with no further comments, clearing the trial to proceed. The planned confirmatory Phase 3 trial, TELLOMAK 3, is an open-label, randomized study designed to demonstrate the efficacy of la.

Business Wire • Nov 10, 2025

Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Innate Pharma (IPHA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Investment Research • Nov 6, 2025

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive V.

Business Wire • Nov 5, 2025

Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript

Innate Pharma S.A. (NASDAQ:IPHA ) Analyst/Investor Day October 28, 2025 8:00 AM EDT Company Participants Jonathan Dickinson - CEO & Director Sonia Quaratino - Executive VP & Chief Medical Officer Stéphanie Cornen Stephanie Cornen - Vice President of Investor Relations, Communication & Commercial Strategy Yannis Morel - Executive VP & COO Conference Call Participants Pierluigi Porcu Chris Stuessy-Vidas Swayampakula Ramakanth - H.C.

Seeking Alpha • Oct 28, 2025

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host an analyst and investor event focused on lacutamab, an asset with path to potential Accelerated Approval based on existing long-term follow-up data of the Phase 2 TELLOMAK study, providing both clinical perspectives and market outlook. The event will be held in person and virtually on Tuesday, October 28, 2025, from 8:00 a.m. to.

Business Wire • Oct 14, 2025